Introduction: GSBR-1290 is a novel, oral, non-peptide GLP-1RA and a potential alternative to injectable or oral peptides used for the treatment of T2DM and obesity. These studies were designed to evaluate the safety, tolerability, and efficacy of GSBR-1290.

Methods: Phase 1b: The safety and tolerability of multiple ascending doses of GSBR-1290 (5-90mg) and its effects on body weight (BW) were investigated in 24 HOV over 4 weeks. Phase 2a: The effects of GSBR-1290 on safety, tolerability, HbA1c, glucose, and BW were investigated in 54 participants with T2DM (45 and 90mg) over 12 weeks and in an interim 8-week analysis of 40 HOV (120mg).

Results: Phase 1b: There were no study discontinuations (d/c) due to adverse events (AEs). Most AEs were mild and GI-related, consistent with GLP-1RAs. BW was significantly reduced (up to 4.9% placebo-adjusted, p=0.013) over 4 weeks. Phase 2a T2DM: Two participants d/c from the study due to an AE (1 attributed to study drug: 2.8% d/c rate). Placebo-adjusted HbA1c (45 mg: -1.01%, p=0.008; 90 mg: -1.02%, p=0.001), BW (45 mg: -3.51%, p=0.0019; 90 mg: -3.26%, p=0.0013), and plasma glucose (45 mg: -2.70, p=0.01; 90 mg: -2.50, p=0.0008) were significantly reduced at day 84. Phase 2a Obesity: There were no study d/c due to AEs. Placebo-adjusted BW decreased though day 56 (120 mg: -4.74%; p<0.0001). Complete 12-week results from the cohort of 24 additional participants will be available at presentation. For all phase 2a, AEs were mild-moderate and GI-related, with no SAEs related to GSBR-1290.

Conclusions: GSBR-1290 demonstrated favorable safety and tolerability in this Phase 1b/2a study in participants with T2DM and in HOV. GSBR-1290 demonstrated clinical benefits in lowering BW, blood glucose, and HbA1c. These data provide clinical proof-of-concept of GSBR-1290 and support further clinical development in T2DM and obesity.

Disclosure

B. Coll: Employee; Structure Therapeutics, Inc. J. Zhang: Employee; Structure Therapeutics, Inc. L. Chen: Employee; Structure Therapeutics, Inc. L. Ibarra: Employee; Structure Therapeutics, Inc. H. Yue: Employee; Structure Therapeutics, Inc. A. Barth: Employee; Structure Therapeutics, Inc. M.A. Bach: Employee; Structure Therapeutics, Inc.

Funding

Structure Therapeutics, Inc

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.